Beam Therapeutics Inc (BEAM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 44.02 is considered Undervalued compared with the five-year average of -10.30. The fair price of Beam Therapeutics Inc (BEAM) is between 35.60 to 42.51 according to relative valuation method. Compared to the current price of 28.69 USD , Beam Therapeutics Inc By Undervalued By 19.41%.

Relative Value

Fair Zone

35.60-42.51

Current Price：28.69

19.41%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Beam Therapeutics Inc (BEAM) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Beam Therapeutics Inc (BEAM) has a current Price-to-Book (P/B) ratio of 2.77. Compared to its 3-year average P/B ratio of 2.42, the current P/B ratio is approximately 14.23% higher. Relative to its 5-year average P/B ratio of 4.38, the current P/B ratio is about -36.84% higher. Beam Therapeutics Inc (BEAM) has a Forward Free Cash Flow (FCF) yield of approximately -13.15%. Compared to its 3-year average FCF yield of -13.34%, the current FCF yield is approximately -1.35% lower. Relative to its 5-year average FCF yield of -7.84%, the current FCF yield is about 67.84% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BEAM competitors is 143.86, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM.O) exhibits a P/S ratio of 44.02, which is -69.4% above the industry average. Given its robust revenue growth of 279.52%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BEAM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BEAM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BEAM currently overvalued or undervalued?

What is Beam Therapeutics Inc (BEAM) fair value?

BEAM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Beam Therapeutics Inc (BEAM) is between 35.60 to 42.51 according to relative valuation method.

How does BEAM's valuation metrics compare to the industry average?

The average P/S ratio for BEAM's competitors is 143.86, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM) exhibits a P/S ratio of 44.02, which is -69.40% above the industry average. Given its robust revenue growth of 279.52%, this premium appears sustainable.

What is the current P/B ratio for Beam Therapeutics Inc (BEAM) as of Mar 03 2026?

As of Mar 03 2026, Beam Therapeutics Inc (BEAM) has a P/B ratio of 2.77. This indicates that the market values BEAM at 2.77 times its book value.

What is the current FCF Yield for Beam Therapeutics Inc (BEAM) as of Mar 03 2026?

As of Mar 03 2026, Beam Therapeutics Inc (BEAM) has a FCF Yield of -13.15%. This means that for every dollar of Beam Therapeutics Inc's market capitalization, the company generates -13.15 cents in free cash flow.

What is the current Forward P/E ratio for Beam Therapeutics Inc (BEAM) as of Mar 03 2026?

As of Mar 03 2026, Beam Therapeutics Inc (BEAM) has a Forward P/E ratio of -5.84. This means the market is willing to pay $-5.84 for every dollar of Beam Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Beam Therapeutics Inc (BEAM) as of Mar 03 2026?

As of Mar 03 2026, Beam Therapeutics Inc (BEAM) has a Forward P/S ratio of 44.02. This means the market is valuing BEAM at $44.02 for every dollar of expected revenue over the next 12 months.

BEAM Valuation